Trial Profile

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Uprosertib (Primary) ; Dabrafenib; Trametinib
Indications Cancer; Lung cancer; Malignant melanoma; Solid tumours; Thyroid cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

14 Jan 2025 Status changed from active, no longer recruiting to completed.
11 Nov 2024 Planned End Date changed from 6 Oct 2024 to 22 Oct 2025.
25 Oct 2023 Planned End Date changed from 31 Dec 2022 to 6 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com